Clot Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type (Fibrin Specific Drugs {Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others} v/s Non-Fibrin Specific Drugs {Urokinase, Streptokinase, Plasminogen Activating Complex}), By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Global clot buster drugs market is anticipated to grow with an impressive CAGR value in the mentioned forecast years 2023-2027 on the account of increasing instances of heart attacks and strokes. Surge in the demand for the effective pharmaceuticals for the immediate response to heart attacks and strokes is further driving the growth of the global clot buster drugs market in the upcoming five years.

Clot buster drugs are the heart diseases dugs that help in dissolving the blood clots in case of blockage in the veins, that are often cause of strokes and heart attack. Clot buster drugs are also known as thrombolytic therapeutics that are a class of heart medications that are often administered under supervisions in the hospitals through an intravenous injection.

Use of these drugs helps in preventing ongoing damage to the heart during heart attack or deteriorating condition due to ischemic stroke. These drugs are also utilized in case the clots are formed in other parts of the blood vessels in the body. Side-effects of these drugs include excessive blood loss from injuries or cuts, allergic reaction to the clot buster drugs, low blood pressure, unusual bleeding in urine, stool etc. thus concerned and monitored administration is a necessity.

Cardiovascular Diseases Drive Market Growth

Increasing instances of cardiovascular diseases are driving the growth of the global clot buster drugs market in the upcoming five years. Rapidly increasing instances of heart attacks, and strokes is also supporting the growth of the global clot buster drugs market in the next five years. Stroke is the 5th leading cause of death in the United States.

Increasing instances of strokes demands for the immediate response to the situation where clot buster drugs can help the situation and dissolve the blood clot pooling in the veins thus creating lower blood pressure. Mortality rate among the population is increasing due to strokes and further aiding the growth of the global clot buster drug market. Death rate from stroke among men in the United States is 37.6 per 100,000 population and that in females is 36.1 per 100,000 population.

Also, increasing risks of ischemic strokes among the global population is further substantiating the growth of the global clot buster drugs market in the next five years. The prevalence of ischemic stroke in women was slightly higher than that in men in 2017. In total, there were 82.42 million people who had experienced an ischemic stroke of which 41.81 million were women and 40.61 were men.


Click here to download the sample

Market Segmentation

The global clot buster drugs market segmentation is based on type, application, distribution channel, regional distribution, and competitive landscape. Based on type, the market is divided between fibrin specific drugs and non-fibrin specific drugs. Further segmentation of fibrin specific drug is defined into tissue plasminogen activator, Reteplase, Tenecteplase, and others.

Whereas non-fibrin specific drugs are differentiated into urokinase, streptokinase, and plasminogen activating complex. Based on application, the market is further segmented into myocardial infarction, pulmonary embolism, deep vein thrombosis, acute ischemic strokes, and others. Distribution channel segment of the market is also fragmented into retail pharmacies, hospital pharmacies, and online pharmacies.

The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

F. Hoffmann-La Roche AG, Taj Pharmaceuticals Limited, Eumedica Pharmaceuticals SA, SEDICO Pharmaceutical Company, Mochida Pharmaceutical Co., Ltd, Medac GmbH, Microbix Biosystems Inc, Crinos S.p.A., are enlisted in a partial list of major market players of the global clot buster drugs market.

The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.

Attribute

Details

Base Year

2021

Historical Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered
  • Type
  • Application
  • Distribution Channel

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, South Africa, UAE, Saudi Arabia, Egypt, Brazil, Argentina, Colombia

Key companies profiled

F. Hoffmann-La Roche AG, Taj Pharmaceuticals Limited, Eumedica Pharmaceuticals SA, SEDICO Pharmaceutical Company, Mochida Pharmaceutical Co., Ltd, Medac GmbH, Microbix Biosystems Inc, Crinos S.p.A.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global clot buster drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Clot Buster Drugs Market, By Type:
    • Fibrin Specific Drugs
      • Tissue Plasminogen Activator
      • Reteplase
      • Tenecteplase
      • Others
    • Non-Fibrin Specific Drugs
      • Urokinase
      • Streptokinase
      • Plasminogen Activating Complex
  • Clot Buster Drugs Market, By Application:
    • Myocardial Infarction
    • Pulmonary Embolism
    • Deep Vein Thrombosis
    • Acute Ischemic Strokes
    • Others
  • Clot Buster Drugs Market, By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Clot Buster Drugs Market, By Region:
    • North America
      • United States
      • Mexico
      • Canada
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Egypt
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global clot buster drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Clot Buster Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Clot Buster Drugs Market

4.    Executive Summary

5.    Voice of Customer

5.1.  Preference, By Drug Type

5.2.  Factors Contributing to Higher Demand of Clot Buster Drugs

5.3.  Barriers to Adoption of Clot Buster Drugs

5.4.  Brand Awareness

6.    Clinical Trials

6.1.  Ongoing Clinical Trials

6.2.  Completed Clinical Trials

6.3.  Terminated Clinical Trials

6.4.  Clinical Trial Analysis

7.    Patent Analysis

7.1.  Patent Granted (2016-2020)

7.2.  Patent Applications Filed

8.    Global Clot Buster Drugs Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)

8.2.1.1.         By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)

8.2.1.2.         By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)

8.2.2.     By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)

8.2.3.     By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

8.2.4.     By Company (2021)

8.2.5.     By Region

8.3.  Product Market Map

9.    North America Clot Buster Drugs Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)

9.2.1.1.         By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)

9.2.1.2.         By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)

9.2.2.     By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)

9.2.3.     By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

9.2.4.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Clot Buster Drugs Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.2.             By Application

9.3.1.2.3.             By Distribution Channel

9.3.2.     Mexico Clot Buster Drugs Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.2.             By Application

9.3.2.2.3.             By Distribution Channel

9.3.3.     Canada Clot Buster Drugs Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.2.             By Application

9.3.3.2.3.             By Distribution Channel

10.  Europe Clot Buster Drugs Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)

10.2.1.1.      By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)

10.2.1.2.      By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)

10.2.2.  By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)

10.2.3.  By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

10.2.4.  By Country

10.3.              Europe: Country Analysis

10.3.1.  France Clot Buster Drugs Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type

10.3.1.2.2.           By Application

10.3.1.2.3.           By Distribution Channel

10.3.2.  Germany Clot Buster Drugs Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type

10.3.2.2.2.           By Application

10.3.2.2.3.           By Distribution Channel

10.3.3.  United Kingdom Clot Buster Drugs Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type

10.3.3.2.2.           By Application

10.3.3.2.3.           By Distribution Channel

10.3.4.  Italy Clot Buster Drugs Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Type

10.3.4.2.2.           By Application

10.3.4.2.3.           By Distribution Channel

10.3.5.  Spain Clot Buster Drugs Market Outlook

10.3.5.1.      Market Size & Forecast

10.3.5.1.1.           By Value

10.3.5.2.      Market Share & Forecast

10.3.5.2.1.           By Type

10.3.5.2.2.           By Application

10.3.5.2.3.           By Distribution Channel

11.  Asia-Pacific Clot Buster Drugs Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)

11.2.1.1.      By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)

11.2.1.2.      By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)

11.2.2.  By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)

11.2.3.  By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

11.2.4.  By Country

11.3.              Asia-Pacific: Country Analysis

11.3.1.  China Clot Buster Drugs Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Type

11.3.1.2.2.           By Application

11.3.1.2.3.           By Distribution Channel

11.3.2.  India Clot Buster Drugs Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Type

11.3.2.2.2.           By Application

11.3.2.2.3.           By Distribution Channel

11.3.3.  South Korea Clot Buster Drugs Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Type

11.3.3.2.2.           By Application

11.3.3.2.3.           By Distribution Channel

11.3.4.  Japan Clot Buster Drugs Market Outlook

11.3.4.1.      Market Size & Forecast

11.3.4.1.1.           By Value

11.3.4.2.      Market Share & Forecast

11.3.4.2.1.           By Type

11.3.4.2.2.           By Application

11.3.4.2.3.           By Distribution Channel

11.3.5.  Australia Clot Buster Drugs Market Outlook

11.3.5.1.      Market Size & Forecast

11.3.5.1.1.           By Value

11.3.5.2.      Market Share & Forecast

11.3.5.2.1.           By Type

11.3.5.2.2.           By Application

11.3.5.2.3.           By Distribution Channel

12.  South America Clot Buster Drugs Market Outlook

12.1.              Market Size & Forecast

12.1.1.  By Value

12.2.              Market Share & Forecast

12.2.1.  By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)

12.2.1.1.      By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)

12.2.1.2.      By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)

12.2.2.  By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)

12.2.3.  By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

12.2.4.  By Country

12.3.              South America: Country Analysis

12.3.1.  Brazil Clot Buster Drugs Market Outlook

12.3.1.1.      Market Size & Forecast

12.3.1.1.1.           By Value

12.3.1.2.      Market Share & Forecast

12.3.1.2.1.           By Type

12.3.1.2.2.           By Application

12.3.1.2.3.           By Distribution Channel

12.3.2.  Argentina Clot Buster Drugs Market Outlook

12.3.2.1.      Market Size & Forecast

12.3.2.1.1.           By Value

12.3.2.2.      Market Share & Forecast

12.3.2.2.1.           By Type

12.3.2.2.2.           By Application

12.3.2.2.3.           By Distribution Channel

12.3.3.  Colombia Clot Buster Drugs Market Outlook

12.3.3.1.      Market Size & Forecast

12.3.3.1.1.           By Value

12.3.3.2.      Market Share & Forecast

12.3.3.2.1.           By Type

12.3.3.2.2.           By Application

12.3.3.2.3.           By Distribution Channel

13.  Middle East and Africa Clot Buster Drugs Market Outlook

13.1.              Market Size & Forecast

13.1.1.  By Value

13.2.              Market Share & Forecast

13.2.1.  By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)

13.2.1.1.      By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)

13.2.1.2.      By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)

13.2.2.  By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)

13.2.3.  By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

13.2.4.  By Country

13.3.              MEA: Country Analysis

13.3.1.  South Africa Clot Buster Drugs Market Outlook

13.3.1.1.      Market Size & Forecast

13.3.1.1.1.           By Value

13.3.1.2.      Market Share & Forecast

13.3.1.2.1.           By Type

13.3.1.2.2.           By Application

13.3.1.2.3.           By Distribution Channel

13.3.2.  Saudi Arabia Clot Buster Drugs Market Outlook

13.3.2.1.      Market Size & Forecast

13.3.2.1.1.           By Value

13.3.2.2.      Market Share & Forecast

13.3.2.2.1.           By Type

13.3.2.2.2.           By Application

13.3.2.2.3.           By Distribution Channel

13.3.3.  UAE Clot Buster Drugs Market Outlook

13.3.3.1.      Market Size & Forecast

13.3.3.1.1.           By Value

13.3.3.2.      Market Share & Forecast

13.3.3.2.1.           By Type

13.3.3.2.2.           By Application

13.3.3.2.3.           By Distribution Channel

13.3.4.  Egypt Clot Buster Drugs Market Outlook

13.3.4.1.      Market Size & Forecast

13.3.4.1.1.           By Value

13.3.4.2.      Market Share & Forecast

13.3.4.2.1.           By Type

13.3.4.2.2.           By Application

13.3.4.2.3.           By Distribution Channel

14.  Market Dynamics

14.1.              Drivers

14.2.              Challenges

15.  Market Trends & Developments

16.  Competitive Landscape

16.1.              F. Hoffmann-La Roche AG

16.2.              Taj Pharmaceuticals Limited

16.3.              Eumedica Pharmaceuticals SA

16.4.              SEDICO Pharmaceutical Company

16.5.              Mochida Pharmaceutical Co., Ltd

16.6.              Medac GmbH

16.7.              Microbix Biosystems Inc

16.8.              Crinos S.p.A.

17.  Strategic Recommendations

18.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

Increasing instances of strokes and heart attacks along with the advancement in the pharmaceutical products are driving the growth of the global clot buster drugs market in the upcoming five years.

down-arrow

The global clot buster drugs market is segmented into North America region, South America region, Asia Pacific region, European region, and Middle East & Africa region for the regional analysis of the market. North America region is anticipated to dominate the market analysis in the upcoming five years on the account of highest count of patients suffering from cardiovascular diseases in the larger economies like the United States, Canada.

down-arrow

F. Hoffmann-La Roche AG, Taj Pharmaceuticals Limited, Eumedica Pharmaceuticals SA, SEDICO Pharmaceutical Company, Mochida Pharmaceutical Co., Ltd among others are some of the leading companies dedicated toward production of clot buster drugs and support the future growth of the global clot buster drugs market in the upcoming five years.

down-arrow

Hospital pharmacies are expected to dominate the global clot buster drugs market segment by distribution channel in the upcoming five years on the account of increasing demand for the drugs toward increasing instances of heart attacks and strokes. Moreover, administration of the drugs must be under supervision thus substantiating the growth of the hospital pharmacies.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Clot Buster Drugs Market to Grow with Impressive CAGR During the Forecast Period

Jan, 2022

Global Clot Buster Drugs Market is driven by increasing heart disease instances in the forecast period, 2023-2027.

Why Choose Us